Join BOPA

Essential resources, easily available.

Our e-learning modules, resources and forums provide oncology pharmacy staff with the tools required to stay abreast of the latest developments to improve patient care.

eLearning

  • Field-specific online modules
  • Supporting certification that can be used to support CPD
  • Keep up to date within the field of oncology pharmacy
  • Stop and continue the course at a time that suits you
Explore eLearning

Your community

  • Innovation through collaboration
  • Communicate with other members of the oncology pharmacy network
  • Share documents and links
  • Submit posts quickly and easily on our interactive forums
Explore community

Resources

  • Access to BOPA publications and position statements
  • Links for further reading and information
  • Checked and verified documents ensures material is current
  • Quick downloads
Explore resources

Latest news

Further news
By BOPA Research Committee on 27th April 2025

SURVEY: Understanding Clinicians’ perceptions of a Decision Support tool for Lung Cancer Treatment

Dear BOPA member, Tarini Deleep and Dr Pinkie Chambers from University College London are developing a risk prediction model to help identify patients with incurable Non Small Cell Lung Cancer,…

Read article
By BOPA on 27th April 2025

Further monographs for use of immunosuppressants in Immune-related adverse events (irAEs)

Earlier this year the BOPA Immunotherapy Group wrote, and published, four monographs to help health care professionals care for patients with immune-related adverse events. As a group we are pleased…

Read article
By BOPA Committee on 27th April 2025

Women for Oncology UK Spring Webinar

The Spring webinar for Women for Oncology UK is on the 16th May, to sign up click the link below. Women For Oncology UK Spring Webinar Tickets, Wed 14 May…

Read article
By BOPA Executive Committee on 25th April 2025

NICE TA: Ribociclib with an aromatase inhibitor can be used as an option for the adjuvant treatment of hormone receptor-positive, HER2-negative, early breast cancer at high risk of recurrence in adults.

BOPA have been involved with the following NICE TA: Ribociclib with an aromatase inhibitor can be used as an option for the adjuvant treatment of hormone receptor-positive, HER2-negative, early breast cancer…

Read article
Further news